These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37648439)

  • 41. Exercise therapy for chronic fatigue syndrome.
    Larun L; Brurberg KG; Odgaard-Jensen J; Price JR
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD003200. PubMed ID: 27995604
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exercise therapy for chronic fatigue syndrome.
    Larun L; Brurberg KG; Odgaard-Jensen J; Price JR
    Cochrane Database Syst Rev; 2016 Jun; (6):CD003200. PubMed ID: 27339435
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exercise therapy for chronic fatigue syndrome.
    Larun L; Brurberg KG; Odgaard-Jensen J; Price JR
    Cochrane Database Syst Rev; 2016 Feb; 2():CD003200. PubMed ID: 26852189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial.
    Bilek F; Cetisli-Korkmaz N; Ercan Z; Deniz G; Demir CF
    Mult Scler Relat Disord; 2022 May; 61():103742. PubMed ID: 35349884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression.
    Richards DA; Rhodes S; Ekers D; McMillan D; Taylor RS; Byford S; Barrett B; Finning K; Ganguli P; Warren F; Farrand P; Gilbody S; Kuyken W; O'Mahen H; Watkins E; Wright K; Reed N; Fletcher E; Hollon SD; Moore L; Backhouse A; Farrow C; Garry J; Kemp D; Plummer F; Warner F; Woodhouse R
    Health Technol Assess; 2017 Aug; 21(46):1-366. PubMed ID: 28857042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial.
    Wahls T; Scott MO; Alshare Z; Rubenstein L; Darling W; Carr L; Smith K; Chenard CA; LaRocca N; Snetselaar L
    Trials; 2018 Jun; 19(1):309. PubMed ID: 29866196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT).
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy EH; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan JR; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J;
    Ann Rheum Dis; 2019 Apr; 78(4):465-472. PubMed ID: 30793700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomised double-blind placebo-controlled feasibility trial of flavonoid-rich cocoa for fatigue in people with relapsing and remitting multiple sclerosis.
    Coe S; Cossington J; Collett J; Soundy A; Izadi H; Ovington M; Durkin L; Kirsten M; Clegg M; Cavey A; Wade DT; Palace J; DeLuca GC; Chapman K; Harrison JM; Buckingham E; Dawes H
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):507-513. PubMed ID: 30833449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Palliative care interventions for people with multiple sclerosis.
    Latorraca CO; Martimbianco ALC; Pachito DV; Torloni MR; Pacheco RL; Pereira JG; Riera R
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012936. PubMed ID: 31637711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.
    de Sèze J; Devy R; Planque E; Delabrousse-Mayoux JP; Vandhuick O; Kabir M; Gherib A
    Mult Scler Relat Disord; 2021 Jan; 47():102659. PubMed ID: 33291032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later.
    Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Duyverman L; van der Zande A; Valkenburg-Vissers J; van Droffelaar M; Lemmens W; Donders R; Visser LH
    BMC Res Notes; 2016 Jul; 9():375. PubMed ID: 27473375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cognitive behavioural therapy for tinnitus.
    Fuller T; Cima R; Langguth B; Mazurek B; Vlaeyen JW; Hoare DJ
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012614. PubMed ID: 31912887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised controlled trial testing the efficacy of Fit after COVID, a cognitive behavioural therapy targeting severe post-infectious fatigue following COVID-19 (ReCOVer): study protocol.
    Kuut TA; Müller F; Aldenkamp A; Assmann-Schuilwerve E; Braamse A; Geerlings SE; Gibney KB; Kanaan RAA; Nieuwkerk P; Olde Hartman TC; Pauëlsen D; Prins M; Slieker K; Van Vugt M; Bleeker-Rovers CP; Keijmel SP; Knoop H
    Trials; 2021 Dec; 22(1):867. PubMed ID: 34857010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical effectiveness, cost-effectiveness and acceptability of low-intensity interventions in the management of obsessive-compulsive disorder: the Obsessive-Compulsive Treatment Efficacy randomised controlled Trial (OCTET).
    Lovell K; Bower P; Gellatly J; Byford S; Bee P; McMillan D; Arundel C; Gilbody S; Gega L; Hardy G; Reynolds S; Barkham M; Mottram P; Lidbetter N; Pedley R; Molle J; Peckham E; Knopp-Hoffer J; Price O; Connell J; Heslin M; Foley C; Plummer F; Roberts C
    Health Technol Assess; 2017 Jun; 21(37):1-132. PubMed ID: 28681717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.